<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544791</url>
  </required_header>
  <id_info>
    <org_study_id>32/07</org_study_id>
    <nct_id>NCT00544791</nct_id>
  </id_info>
  <brief_title>The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment</brief_title>
  <acronym>MCI</acronym>
  <official_title>The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurim Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have described the role of melatonin as a sleep regulator and as an anti-
      oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in
      Alzheimer's disease (AD).

      In accordance with this data, our hypothesis is that melatonin will delay the cognitive
      decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI
      to AD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a delay in cognitive decline as measured by memory tests</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced MCI conversion rate to AD per year</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mild Cognitive Impairment (MCI)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 5 mg, daily dose for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>5 mg, oral, daily dose for 6 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo like melatonin tablets</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. MCI assessment according to the Peterson et al. (2001) criteria.

          2. Age 55-90 years, inclusive.

          3. Study informant available.

          4. Mini Mental Status Examination ; MMSE 24-30.

          5. Adequate vision and hearing for neuropsychological testing.

          6. Normal vitamin B12 level and thyroid function.

        Exclusion Criteria:

          1. Significant cerebral vascular disease (Modified Hachinski scale &gt; 4).

          2. Depression (Hamilton Depression Rating Scale &gt; 12).

          3. Central nervous system infarct, infection or focal lesions of clinical significance on
             CT or MRI scans.

          4. Medical diseases or psychiatric disorders that could interfere with study
             participation.

          5. Pregnant, lactating or childbearing potential.

          6. Taking vitamin supplements or other supplements.

          7. Restrictions on concomitant medication usage, including those with significant
             cholinergic or anti-cholinergic effects or potential adverse effects on cognition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micheal khaigrekht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh medical center, Memory clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Rabey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh medical center, Neurology department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Itzhak Sphirer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh medical center, sleep lab</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ran Shorer, MA</last_name>
    <role>Study Chair</role>
    <affiliation>Asaf Harofeh medical center, Memory clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael khaigrekht, MD</last_name>
    <phone>972-8-9779823</phone>
    <email>khaigrekhtm@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Rabey, MD</last_name>
    <phone>972-8-9779755</phone>
    <email>RabeyM@asaf.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memory clinic, 'Asaf Harofeh' medical center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Khaigrekht, MD</last_name>
      <phone>972-8-9779823</phone>
      <email>Khaigrekhtm@asaf.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Ran Shorer, MA</last_name>
      <phone>972-8-9779755</phone>
      <email>shorer@asaf.health.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2007</study_first_submitted>
  <study_first_submitted_qc>October 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>October 15, 2007</last_update_submitted>
  <last_update_submitted_qc>October 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2007</last_update_posted>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Memory</keyword>
  <keyword>Alzheimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

